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During the fall/winter season of 2004–05, we found 9
respiratory specimens positive for human parainfluenza
virus type 4 (HPIV-4) in our laboratory (43% of all HPIVs)
from patients with mild to moderate respiratory illnesses.
Sequencing studies identified 8 different HPIV-4A strains
and 1 HPIV-4B strain.
H
uman parainfluenza viruses (HPIVs) have been rec-
ognized as a cause of respiratory tract infections for
many decades. They belong to the Paramyxoviridae fami-
ly, subfamily Paramyxovirinae, and are classified into 4
serotypes. Serotype 4 can be further subdivided into 2 anti-
genic subtypes, HPIV-4A and HPIV-4B (1). Although the
epidemiology and clinical manifestations of serotypes
HPIV-1 to HPIV-3 are well described, much less is known
about HPIV-4, including its seasonality (2).
HPIV-4 has been mostly associated with mild illnesses
(3,4). However, some evidence has indicated that it can
cause more severe infections in some settings (5–10). We
sought to describe the virologic and molecular characteris-
tics as well as the clinical manifestations associated with
HPIV-4 infections at our hospital during 2004–05.
The Study
From October 20, 2004, to March 8, 2005, we found 9
respiratory specimens positive for HPIV-4 in our virology
laboratory. Specimens were collected from patients who
were either admitted to a tertiary care hospital, seeking
treatment at its emergency room, or attending an outpatient
clinic connected to that hospital.
Specimens were placed into 96-well plates seeded with
8 cell lines and onto 2 shell vials (Table 1). Viral cultures
were incubated for 21 to 24 days. For LLC-MK2 and
MDCK cells, a hemadsoption test was performed at the
end of the incubation period. Cytopathic effects (CPEs) or
positive hemadsorption tests were confirmed by using
immunofluorescence assays performed with monoclonal
antibodies against HPIV-4 (Chemicon International,
Temecula, CA, USA).
Viral RNA was extracted from culture supernatants by
using the MagaZorb RNAMini-prep kit (Cortex Biochem,
San Leandro, CA, USA) and then tested with RT-PCR by
using the Qiagen one-step RT-PCR kit. Amplicons of the
fusion (F; 1631 nt) and hemagglutinin-neuraminidase
(HN; 1721 nt) genes were generated by using primers list-
ed in Table 1. Nucleotide sequences of all HPIV-4 strains
were determined and entered into a multiple alignment
generated by the Clustal W software (version 1.83)(11).
Phylogenetic analyses were performed using distance
methods with the PAUP software (version 4.0b10; Sinauer
Associates, Sunderland, MA, USA).
Positive HPIV-4 samples consisted of 7 nasopharyngeal
aspirates and 2 nasopharyngeal or throat swab specimens.
The 9 viruses grew only in LLC-MK2 cells with all but
one demonstrating CPEs from 12 to 21 days post-inocula-
tion (mean: 19 days). The CPEs consisted of large and
round swollen cells that progressed to destruction of the
monolayer, without syncytium formation. The hemadsorp-
tion test result was positive for all isolates with subsequent
confirmation by immunofluorescence staining. No other
virus grew on the other cell lines. Bacterial cultures were
done for 4 patients, and 1 culture was positive for
Streptococcus pneumoniae.
Between October 20, 2004, and March 8, 2005, 1,424
respiratory specimens were submitted to our virology lab-
oratory for viral culture. Of these, 371 (26%) were positive
for a virus. HPIV-4 was the most frequent HPIVwith 9 iso-
lates, representing 43% of all HPIVs and 2.4% of all posi-
tive cultures. During the same period of 2003–04, we
isolated only 1 HPIV-4 (2% of all HPIVs and 0.3% over-
all). In 2002–03, eleven HPIV-4 were recovered (23% of
all HPIVs and 7.0% overall). Finally during the 2001-02
season, we found 3 HPIV-4 (15% of all HPIVs and 0.8%
overall) (Figure 1).
The 9 HPIV-4 positive patients consisted of 6 children
(5 <6 months of age) and 3 adults (Table 2). Among the
pediatric patients, 3 had bronchiolitis, and the youngest
(1.5 months) required a stay in the intensive care unit
because of apnea. Two of the 3 patients with bronchiolitis
had paroxysmal cough, and pertussis was suspected. The
other 3 patients had upper respiratory tract illnesses.
Among those 6 patients, 2 received antimicrobial drugs,
and all recovered.
Among the 3 adults, 1 was 25 years of age, and 2 were
>80 years of age. The former had pharyngitis and buccal
ulcerative lesions. No other viral or bacterial pathogen was
found. An 84-year-old woman was admitted to the hospi-
tal for severe bronchospasm and suspected pulmonary
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 11, November 2006 1755
*Research Center in Infectious Diseases of the Centre Hospitalier
Universitaire de Québec, Quebec City, Quebec, Canada;  †Laval
University, Quebec City, Quebec, Canada; and ‡Centre
Hospitalier Régional du Grand-Portage, Rivière-du-Loup, Quebec,
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ness but antigenic test results were negative for influenza.
The 3 patients had no complications and survived. Overall,
4 of the 9 patients were hospitalized with a mean length of
stay of 8 days (range 2–14 days). Six (66%) of the patients
had an underlying disease.
Phylogenetic trees of the F and HN genes were similar.
Eight different HPIV-4 isolates clustered with the HPIV-
4A reference strain, whereas the remaining one clustered
with the HPIV-4B reference strain (Figure 2). The percent-
ages of nucleotide (nt)/amino acid (aa) identity for the 8
HPIV-4A strains were 97%/100% (F gene) and 97%/99%
(HN gene). In contrast, the percentages of nt/aa identity
between the HPIV-4A strains and the HPIV-4B isolate
were 89%/92% (F gene) and 86%/87% (HN gene).
Conclusions
HPIV-4 is considered a rare pathogen because it has
been isolated only occasionally from respiratory tract
specimens, although seroprevalence studies have shown
that 70%–90% of young adults have specific antibodies
against it (12,13). Lately, a few reports have shown that
HPIV-4 might be more frequent than previously thought
when sensitive RT-PCR methods are used (5,8,10,14).
Using viral cultures, we found that HPIV-4 accounted for
43% of all HPIVs isolated in our laboratory during the
2004-05 fall and winter seasons. Direct testing of clinical
specimens with RT-PCR would have likely resulted in
higher detection rates.
Possible explanations for the rarity of HPIV-4 are in
part related to its slow growth in LLC-MK2 cells, a cell
line not used in most virology laboratories. Also, CPEs are
not always present (may take 2–3 weeks to appear), and
the hemadsorption reaction is occasionally weak (1).
Finally, symptoms associated with HPIV-4 are generally
mild and do not elicit requests for a cell culture.
To our knowledge, no seasonality has been described
for HPIV-4. In our area, HPIV-4 was isolated every year
during the last 4 years with peaks of activity occurring
every other year, similar to HPIV-1 and 2 (15). The
biennial pattern of HPIV-4 would require confirmation in
larger studies from other countries. In temperate countries,
the virus is usually recovered during the late fall and win-
ter seasons (2,13,14). In fact, over the last 4 years, only 4
HPIV-4 isolates were recovered outside our study period,
3 in April and 1 in May.
The retrospective aspect of our study and the small
number of viral isolates limit definitive conclusions on the
clinical manifestations of HPIV-4 infections. We note that
young children were preferentially affected as previously
reported (2,5–7,14) although they also constitute the most
likely population for whom viral cultures would be
obtained. In children, clinical conditions included upper
respiratory tract infections, bronchiolitis, and pertussislike
clinical syndromes (7). Infected adults had various clinical
presentations, i.e., pharyngitis, bronchospasm, and flulike
illnesses, although further work is required to describe the
full clinical spectrum of HPIV-4 infections.
Our 9 HPIV-4 isolates could be further subdivided into
8 different HPIV-4A and 1 HPIV-4B strains, according to
sequences obtained from the 2 glycoproteins F and HN.
Reports of HPIV-4B infection have been infrequent in the
last 2 decades, similar to our findings (9).
In summary, HPIV-4 infections can be relatively com-
mon during the fall and winter seasons of some years and
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Figure 1. Seasonality of human parainfluenza virus type 4 (HPIV-
4) infections during fall and winter of 4 consecutive years. are probably underdiagnosed due to their fastidious
growth. Detection of this respiratory pathogen needs to be
improved through rapid molecular assays.
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